Yakov Datsenko

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 374 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

Mark Sulkowski, Tarik Asselah, Jacob Lalezari et al. · Hepatology · 2013 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Ulrich Mrowietz, A. David Burden, Andreas Pinter et al. · Dermatology and Therapy · 2021 · 93 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki et al. · Hepatology · 2013 · 68 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

Mark Sulkowski, E. Ceasu, Tarik Asselah et al. · Journal of Hepatology · 2011 · 39 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14